Altered behaviors associated with LSD may be caused by a reduction in the normal communication between the hippocampus and visual cortex.
One dose of psilocybin, the psychoactive compound found in magic mushrooms, increases dendritic spine density within 24 hours. The neurobiological changes lasted for a month following psilocybin exposure. Additionally, mice subjected to stress showed behavioral improvements and increased neurotransmitter activity after psilocybin exposure.
A single dose of tabernanthalog (TBG), a non-hallucinogenic psychedelic analog, corrects stress-induced behavioral deficits, including anxiety and cognitive inflexibility, in mouse models. Additionally, the compound promoted neurogenesis and restores neural circuits in brain areas damaged by stress.
PsychLight, a newly developed genetically encoded fluorescent sensor, helped researchers identify a psychedelic compound that acts on beneficial neural pathways to treat psychiatric disorders without the hallucinogenic effect.
Psilocybin, the psychoactive compound found in magic mushrooms, is as effective at treating depression as conventional SSRI antidepressants. Researchers report, that although not significantly significant, early findings reveal those treated with psilocybin experienced more rapid and greater reductions in depression symptoms than those treated with SSRIs.
A mouse study refutes the common belief that psilocybin's ability to produce an anti-depressant effect is attributed to the psychedelic experience it creates. Blocking the psychedelic effect did not affect psilocybin's anti-depressant effects.
As interest in using psychedelics to treat a range of mental health disorders grows, researchers consider the impact and therapeutic benefits of using psychedelics to help alleviate symptoms of depression.
While the effects of hallucinogens to treat mental illnesses are being researched, little is known about the neurobiology of those who dabble in psychedelics for recreational purposes. A new study reports "psychonauts" have distinct behaviors, including taking a scientific approach to documenting their experience with hallucinogens, compared to more recreational users.
From microdosing to improve cognition, to treating a range of mental health disorders, researchers evaluate the rise in the use of psychedelics and their potential as medicines.